Elisa G.
- Country
- Italy
- Department
- Medical Oncology Department - ASST - Sette Laghi
Research Overview
- Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study
- Phase III Randomized Trial of Adjuvant Avelumab in High-Risk Triple Negative Breast Cancer Post-Curative Treatment
- A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPa
Data & Insights
Has run more than one trial at 32 of 239 partner sites.
Specializations
Breast Cancer Specialization
This investigator demonstrates significant expertise in breast cancer treatment, with particular focus on complex therapeutic approaches for different breast cancer subtypes.
- HER2-positive breast cancer management
- Triple-negative breast cancer treatment
- Hormone receptor-positive disease therapy
The investigator's work encompasses both early-stage and high-risk breast cancer cases.
Targeted Therapies
The investigator specializes in implementing novel targeted therapeutic approaches for breast cancer treatment, including:
- PI3K inhibition strategies
- HER2-targeted therapies
- PARP inhibitor applications
- Immunotherapy approaches
Their research integrates multiple targeted agents in combination treatment strategies.
Treatment Approaches
The investigator focuses on developing comprehensive treatment protocols across different stages of breast cancer care:
- Neoadjuvant therapy optimization
- Adjuvant treatment strategies
- Endocrine therapy combinations
- Immunological interventions
Their work emphasizes personalized treatment approaches based on specific genetic and molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.